2017-000457-39
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C->T or D1152H CFTR Mutation
Vertex Pharmaceuticals Incorporated·EU Clinical Trials Register
Study focus
- Disease/Condition
- Cystic Fibrosis
Sponsor & location
- Primary sponsor
- Vertex Pharmaceuticals Incorporated
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
Change in lung clearance index 2.5
ICD-10 classifications
Cystic fibrosisCystic fibrosis, unspecifiedCystic fibrosis with other manifestationsCystic fibrosis with pulmonary manifestationsCystic fibrosis with intestinal manifestations
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2017-000457-39
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2017-000457-39 through Pure Global AI's free database. This phase not specified trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently status unknown. The study focuses on Cystic Fibrosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.